Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2021 | Selinexor in myelofibrosis treatment

Michael Deininger • 12 Dec 2021
ASH 2021
Myelofibrosis Myeloproliferative Neoplasms Selinexor

Selinexor inhibits karyopherin protein exportin 1 (XPO1) activity and is currently approved for diffuse large B-cell lymphoma (DLBCL) and multiple myeloma. Michael Deininger, MD, PhD, University of Utah, Salt Lake City, UT, provides an overview of the rationale behind using selinexor in treating myelofibrosis. Currently, there are limited treatment options for myelofibrosis, especially in patients resistant to Janus kinase (JAK) inhibitors. Preliminary studies have indicated clinical efficacy and safety in patients with myelofibrosis. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

More from Michael Deininger

1:24
Ongoing studies in CML: investigating asciminib toxicity and improving TFR rates
Michael Deininger • 21 Oct 2022
1:09
Tolerability of bosutinib vs asciminib in heavily pre-treated patients with CML
Michael Deininger • 21 Oct 2022
1:33
ESH CML workshop highlights: 3D genomics and nuclear organization
Michael Deininger • 21 Oct 2022
1:10
Final results of the BFORE trial: bosutinib vs imatinib in CP-CML
Michael Deininger • 21 Oct 2022

Related Videos

1:13
The current BSH guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
Mary Frances McMullin • 28 Apr 2024
1:46
Updated analyses from the PATHFINDER trial: avapritinib therapy in advanced systemic mastocytosis
Deepti Radia • 29 Apr 2024
4:32
Current trials in MPN in the UK and the launch of the My MPN Voice app
Claire Harrison • 29 Apr 2024
2:42
The management of myelofibrosis in patients with moderate to severe anemia
Mary Frances McMullin • 28 Apr 2024
The content of VJHemOnc is intended for healthcare professionals